GMYTF yields 1.91% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 5
Combined, GMYTF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GMYTF + JNJ for your $10,000?
GMO Payment Gateway, Inc., together with its subsidiaries, provides financial services and integrated payment related services. It operates through three segments: Payment Enhancement Business, Payment Processing Business, and Money Service Business. The company offers PG multi-payment service, a payment platform that provides credit card payment, convenience store payment, account transfer, and multi-currency credit card payment. It also provides GMO payment after delivery; Ginko Pay Base System, a smartphone app that enables payments to be made by an immediate debit from the bank account; and GMO-PG processing platform, which helps financial institutions or financial service providers start payment-related services by enabling payment infrastructure building, as well as security services. In addition, the company offers global payment services; and early payment, GMO-PG remittance, guarantees, and transaction lending services. Further, it offers online advertising services consisting of administrative services for listing ads that use Yahoo! Promotional Ads and Google AdWords; and administrative services for Facebook Ads, Google Analytics, etc. It serves online merchants and public organizations, such as NHK, National Tax Agency, and Tokyo Metropolitan Government; and banks and other financial institutions. GMO Payment Gateway, Inc. was founded in 1995 and is headquartered in Tokyo, Japan.
Full GMYTF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.